Clinical Trials Search at Vanderbilt-Ingram Cancer Center
REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED0710
Infectious Disease Outcomes in Pediatric Oncology Patients
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED14127
Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Kitko, Carrie
VICCPED1544
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Friedman, Debra
COGAPEC14B1
Survivorship in Patients Receiving Immune Checkpoint Inhibitors
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Johnson, Douglas
VICCMEL15138
Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Tindle, Hilary
VICCTHO1886
Pattern of Changes in Immune Profile in the Setting of Chimeric Antigen Receptor T-Cell Therapy
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Oluwole, Olalekan
VICCCTT2074
Patient and Health Care Provider Perspectives of Naloxone
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Hande, Karen
VICCSUPP2068
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Miscellaneous
Miscellaneous
This is an observational case-control study to train and validate a genome-wide methylome
enrichment platform to detect multiple cancer types and to differentiate amongst cancer
types. The cancers included in this study are brain, breast, bladder, cervical, colorectal,
endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma,
multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers
were selected based on their prevalence and mortality to maximize impact on clinical care.
Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal
residual disease after completion of cancer treatment and to detect relapse prior to clinical
presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate).
These cancers were selected based on the existing clinical landscape and treatment
availability.
enrichment platform to detect multiple cancer types and to differentiate amongst cancer
types. The cancers included in this study are brain, breast, bladder, cervical, colorectal,
endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma,
multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers
were selected based on their prevalence and mortality to maximize impact on clinical care.
Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal
residual disease after completion of cancer treatment and to detect relapse prior to clinical
presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate).
These cancers were selected based on the existing clinical landscape and treatment
availability.
Miscellaneous
N/A
Rini, Brian
NCT05366881
VICCMD21111